Louisiana’s abortion drug access law heightens hemorrhage risk for pregnant patients

Louisiana's 2024 law reclassifying misoprostol as a controlled substance forced hospitals to store it securely, delaying access during emergencies. The drug is critical for treating pregnancy-related hemorrhages but is now harder to retrieve, increasing patient risk. The law also reclassified mifepristone, further complicating reproductive healthcare access.